2024-09-25 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company known for its innovative medications in areas like diabetes, oncology, and neurology.

**Performance Analysis:**

**1. Return Rate & Relative Performance:**

* **LLY Cumulative Return:** 893.18%
* **S&P 500 (VOO) Cumulative Return:** 133.37%
* **Performance Difference:** 759.81% (94.22% relative to historical range)

LLY has significantly outperformed the S&P 500 over the analyzed period. This indicates a strong track record of growth and investor confidence in the company.

**2. Recent Price Movements:**

* **Closing Price:** 922.0
* **5-day Moving Average:** 914.94
* **20-day Moving Average:** 925.73
* **60-day Moving Average:** 898.85

The price is currently trading slightly below its 20-day moving average, suggesting potential consolidation or a minor retracement. The 60-day moving average, however, is below the current price, indicating an upward trend.

**3. Technical Indicators:**

* **RSI:** 41.53
* **PPO:** -0.3
* **Delta_Previous_Relative_Divergence:** -5.08 (Short-term decline)
* **Expected Return:** 9.34% (5-year expected return on invested capital)

The RSI suggests that the stock is neither overbought nor oversold. The PPO indicates a slight negative momentum. The recent relative divergence suggests a short-term decline, although the expected return remains positive.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

* **Most Recent Earnings:** 3.29 EPS (Aug 2024).  Analysts had estimated an EPS of 3.27, indicating a slight beat. 

Eli Lilly continues to demonstrate consistent growth in revenue and earnings, driven by strong demand for its key products. The company's focus on research and development in key therapeutic areas, coupled with its strong brand reputation and global reach, suggests a promising outlook for future earnings.

**5. News & Recent Issues:**

* **Recent Market Outlook for LLY:**  The stock has been steadily gaining momentum, fueled by strong earnings results and positive market sentiment. Several analysts have upgraded their ratings on the stock, citing its robust pipeline of new drugs and its leading position in key therapeutic areas.
* **Analyst Opinions and Performance Highlights:** FINBOLD reports that LLY remains a top pick for many analysts, with several citing its potential for continued growth and its strong track record of innovation. Recent positive headlines regarding its clinical trial successes further solidify its position as a leader in the pharmaceutical industry.

**6. Overall Analysis:**

Eli Lilly and Co (LLY) presents a compelling investment opportunity. The company has a strong track record of growth and innovation, supported by consistent revenue and earnings growth.  Recent positive news and analyst sentiment suggest a favorable market outlook. While there are short-term price fluctuations, the long-term trend remains positive, supported by the company's strong fundamentals and its potential for future success. Investors may consider LLY as a strong addition to their portfolio, particularly those seeking exposure to the pharmaceutical sector.

**7. Disclaimer:** This analysis is for informational purposes only and should not be considered as financial advice. Please consult with a qualified financial professional before making any investment decisions.